NUCLEIC ACID MOLECULES ENCODING HUMANIZED IL-31 MONOCLONAL ANTIBODIES

• US 20180305448A1
• Filed: 04/26/2018
• Published: 10/25/2018
• Est. Priority Date: 12/07/2007
• Status: Active Grant

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company), Merck Serono SA (Merck & Co., Inc.)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company), Merck Serono SA (Merck & Co., Inc.)
• Inventors: Bondensgaard, Kent, Beckmann, Roland
• Granted Patent: US 10,640,559 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 39/00114 Interleukins [IL]
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/51 Complete heavy chain or Fd fragment, i.e. VH + CH1
• CPC Class Codes: C07K 2317/515 Complete light chain, i.e. VL + CL
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: C12N 15/63 Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• CPC Class Codes: C12N 5/10 Cells modified by introduction of foreign genetic material

Abstract

The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.

Claims

1. An isolated nucleic acid molecule encoding a humanized monoclonal antibody that specifically binds to human IL-31, wherein the encoded monoclonal antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:

47 and the light chain comprises the amino acid sequence of SEQ ID NO;

46.

2. An expression vector comprising the following operably linked elements:

a) a transcription promoter;

b) the nucleic acid molecule of claim 1; and

c) a transcription terminator.

3. An expression vector comprising the following operably linked elements:

a) a first transcription promoter;

b) a first nucleic acid molecule encoding the heavy chain of claim 1;

c) a first transcription terminator;

d) a second transcription promoter;

e) a second nucleic acid molecule encoding the light chain of claim 1; and

f) a second transcription terminator.

4. An expression vector comprising the following operably linked elements:

a) a first transcription promoter;

b) a first nucleic acid molecule encoding the heavy chain of claim 1;

c) a first transcription terminator;

d) the first transcription promoter;

e) a second nucleic acid molecule encoding the light chain of claim 1; and

f) a second transcription terminator.

5. A recombinant host cell comprising the expression vector of claim 2.

6. A recombinant host cell comprising the expression vector of claim 3.

7. A recombinant host cell comprising the expression vector of claim 4.

8. A method of producing the IL-31 monoclonal antibody encoded by the nucleic acid molecule in the expression vector of claim 2 comprising:

a) culturing a host cell comprising said vector under conditions wherein the monoclonal antibody is expressed; and

b) recovering the monoclonal antibody.

9. A method of producing the IL-31 monoclonal antibody encoded by the nucleic acid molecule in the expression vector of claim 3 comprising:

a) culturing a host cell comprising said vector under conditions wherein the monoclonal antibody is expressed; and

b) recovering the monoclonal antibody.

10. A method of producing the IL-31 monoclonal antibody encoded by the nucleic acid molecule in the expression vector of claim 4 comprising:

a) culturing a host cell comprising said vector under conditions wherein the monoclonal antibody is expressed; and

b) recovering the monoclonal antibody.